The global cell and gene therapy market is experiencing significant growth as advancements in biotechnology and personalized medicine transform the treatment of complex diseases. According to Fortune Business Insights, the global cell and gene therapy market size was valued at USD 12.21 billion in 2025. The market is projected to grow from USD 16.45 billion in 2026 to USD 143.55 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 31.10% during the forecast period. North America dominated the market with a share of 52.58% in 2025.
Cell and gene therapies are advanced medical treatments designed to address diseases at the cellular or genetic level. Cell therapy involves introducing, modifying, or replacing cells to restore biological functions, while gene therapy focuses on modifying or delivering genetic material to treat specific conditions. These approaches are increasingly utilized in oncology, rare genetic disorders, hematological diseases, and other medical applications.
Key Market Growth Drivers
Increasing Prevalence of Cancer and Rare Diseases
The rising prevalence of cancer and rare genetic disorders is a major factor driving market growth. Conventional treatments may provide limited outcomes for certain complex diseases, creating demand for advanced therapeutic approaches.
Cell and gene therapies offer targeted treatment possibilities for patients with significant unmet medical needs. CAR-T cell therapies, for example, are increasingly utilized in selected hematological malignancies. Gene therapies are also being developed to address inherited disorders by modifying or replacing defective genetic material.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cell-and-gene-therapy-market-114130
Advancements in Biotechnology
Continuous advancements in genetic engineering, cell modification, viral vector development, and genome editing are supporting market expansion. Technologies such as CRISPR and advanced cell engineering are enabling researchers to develop more precise therapeutic approaches.
Improved manufacturing techniques and analytical technologies are helping companies enhance treatment quality and consistency. Increasing research investments and clinical development activities are further strengthening the market.
Increasing Regulatory Approvals
Growing regulatory approvals for advanced therapies are supporting commercialization. The availability of approved treatments is encouraging healthcare providers to incorporate cell and gene therapies into selected treatment pathways.
Regulatory progress also improves confidence among investors, biotechnology companies, and healthcare institutions, supporting further market development.
Emerging Market Trends
The shift toward allogeneic and off-the-shelf therapies is an important trend. Unlike autologous therapies, which utilize a patient's own cells, allogeneic treatments can be developed using donor cells and potentially manufactured in larger standardized batches. This approach may improve scalability and treatment accessibility.
Another major trend is the increasing adoption of automated manufacturing technologies. Companies are investing in specialized production facilities, process automation, and advanced quality-control systems to improve manufacturing efficiency.
Strategic partnerships between biotechnology companies, pharmaceutical manufacturers, research institutions, and healthcare providers are also expanding. These collaborations support clinical development, technology transfer, commercialization, and manufacturing capacity.
Market Segmentation
By Type
The market is segmented into cell therapy and gene therapy.
Cell therapy dominated the market due to its commercial adoption in oncology and the availability of approved treatments. CAR-T cell therapy, TCR-T cell therapy, and natural killer cell-based approaches are important technologies within this segment.
Gene therapy is expected to grow at a CAGR of 21.97% during the forecast period. Increasing research into genetic diseases, ophthalmological disorders, and hematological conditions is supporting segment expansion.
By End User
The market is categorized into hospitals and clinics, specialty clinics, and others.
Hospitals and clinics represent the leading end-user segment due to their specialized infrastructure, multidisciplinary healthcare teams, and ability to manage complex treatment procedures. These facilities provide patient assessment, therapy administration, monitoring, and follow-up care.
Specialty clinics are projected to grow at a CAGR of 32.79% during the forecast period. Increasing specialization in advanced therapies and expanding treatment capabilities are supporting growth.
Regional Outlook
North America
North America dominated the market, reaching USD 6.42 billion in 2025. The region benefits from advanced healthcare infrastructure, biotechnology research capabilities, strong pharmaceutical investment, and regulatory development. The U.S. market is estimated to reach USD 7.95 billion in 2026.
Europe
Europe is projected to reach USD 4.47 billion in 2026. The region benefits from established biotechnology industries, clinical research infrastructure, and increasing adoption of advanced medical treatments. Germany and the U.K. are important contributors.
Asia Pacific
Asia Pacific is estimated to reach USD 2.18 billion in 2026. Increasing healthcare investments, expanding biotechnology research, and growing demand for innovative treatments are supporting regional growth. Japan and China are significant markets.
Latin America
Latin America is expected to reach USD 0.67 billion in 2026. Improvements in healthcare infrastructure and increasing interest in advanced therapeutic technologies are supporting market development.
Middle East & Africa
The GCC market is projected to reach USD 0.33 billion in 2026. Healthcare modernization and investments in specialized treatment infrastructure are contributing to regional opportunities.
Competitive Landscape
Major companies operating in the market include Vertex Pharmaceuticals Incorporated, Novartis AG, Bristol Myers Squibb Company, Krystal Biotech, Inc., Rocket Pharmaceuticals, F. Hoffmann-La Roche Ltd., Bayer AG, CRISPR Therapeutics, Gilead Sciences, Inc., and Adaptimmune.
Companies are focusing on research and development, product approvals, strategic collaborations, acquisitions, and manufacturing expansion to strengthen their competitive positions.
Challenges and Opportunities
High treatment costs, complex manufacturing processes, reimbursement limitations, and regulatory requirements remain major challenges. Personalized therapies also require specialized logistics, quality control, and patient monitoring.
However, growing demand for innovative treatments, manufacturing automation, and investment in biotechnology infrastructure creates significant opportunities.
Conclusion
The Cell and Gene Therapy Market is expected to experience substantial growth through 2034, driven by biotechnology advancements, rising disease burden, and increasing commercialization of advanced treatments. Cell therapy currently holds a leading position, while gene therapy offers considerable growth potential. Continued investment in research, manufacturing technologies, and strategic partnerships is expected to strengthen the industry's long-term development.
Comments